Telmisartan
Rank #459 of 500 drugs by total cost
Data: CMS Medicare Part D, 2023 (most current available) · Updated March 2026
$16.4M
Total Cost
334,601
Total Claims
$16.4M
Total Cost
11,815
Prescribers
$49
Cost per Claim
46,533
Beneficiaries
827,512
30-Day Fills
$1,389
Avg Cost/Provider
28
Avg Claims/Provider
Share of Medicare Part D Spending
0.01%
of total Medicare Part D spending
$16.4M of $275.65B
Top Prescribers by Cost
Top 10 prescribers of $16.4M total
Top Prescribers of Telmisartan
| # | Provider | Specialty | Location | Claims | Cost |
|---|---|---|---|---|---|
| 1 | Cres Miranda | Cardiology | Las Vegas, NV | 990 | $49K |
| 2 | Ajitpal Tiwana | Family Practice | Bakersfield, CA | 456 | $33K |
| 3 | Anthony Gunawan | Cardiology | Houston, TX | 498 | $27K |
| 4 | Anthony Defranco | Interventional Cardiology | Milwaukee, WI | 529 | $26K |
| 5 | Hung Dang | Family Practice | Arlington, TX | 241 | $25K |
| 6 | John Woodcock | Family Practice | Palmdale, CA | 400 | $23K |
| 7 | Michael Harris | Internal Medicine | Bend, OR | 529 | $22K |
| 8 | Vidyasagar Chodimella | Cardiology | Carrollton, TX | 479 | $22K |
| 9 | Michael Maxwell | Internal Medicine | Tulsa, OK | 297 | $22K |
| 10 | Huy Nguyen | Internal Medicine | Fort Worth, TX | 255 | $21K |
| 11 | Raul Santoscoy | Family Practice | San Antonio, TX | 248 | $21K |
| 12 | Michael Dangovian | Cardiology | Sterling Hgts, MI | 332 | $20K |
| 13 | Matthew Teltser | Cardiology | Davie, FL | 289 | $20K |
| 14 | Jose Escandon | Internal Medicine | Mission, TX | 327 | $20K |
| 15 | Anhtuan Nguyen | Internal Medicine | Westminster, CA | 401 | $20K |
Top prescribers ranked by total cost for this drug in 2023.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 456 | Clonidine (Clonidine) | $16.7M | 112,710 |
| 457 | Glucagon (Gvoke Hypopen 2-Pack) | $16.6M | 31,523 |
| 458 | Bosentan (Bosentan) | $16.5M | 2,765 |
| 459 | Telmisartan (Telmisartan) | $16.4M | 334,601 |
| 460 | Letermovir (Prevymis) | $16.1M | 2,144 |
| 461 | Fluphenazine Hcl (Fluphenazine Hcl) | $16.0M | 73,051 |
| 462 | Nivolumab (Opdivo) | $16.0M | 1,275 |
Related Analysis
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology